openPR Logo

Press Releases from BOC Sciences (9 total)

BOC Sciences Unveils Comprehensive Capabilities of Custom Peptide Drug Conjugate

BOC Sciences, a leading CRO in the USA, unveils its comprehensive capabilities for custom peptide drug conjugate from project design to commercial production. With its well-established conjugation platform, BOC Sciences supports pharmaceutical and biotechnology clients at the forefront of drug conjugation. Peptide-drug conjugates (PDCs) are mainly used in anti-cancer therapy, which integrates the advantages of small molecular weight, high tumor penetration, low immunogenicity, large-scale synthesis using solid phase synthesis, low

BOC Sciences Confirms Bulk Offering of Pharmaceutical Impurities for Global Part …

In the wake of the COVID-19 pandemic, BOC Sciences, the world's reputed chemical supplier, declares that it will increase production to offer pharmaceutical impurity standards in bulk to satisfy unmet demands. Innovations in manufacturing processes, more complicated formulations, and increasingly complex global supply chains are just some of the factors making it more difficult for companies to assess and control impurities in drug substances and drug products. BOC Sciences is confident to employ

High-Standard Fermented Raw Materials that Satisfy the Quality Attributes of Hea …

New York, United States-Oct 12, 2022-Managing raw materials as part of the quality system will ensure that all finished healthcare products can meet quality attributes. As a comprehensive supplier of CRO/CMO/CDMO fermentation services, BOC Sciences is able to provide clients with high-standard raw materials to ensure quality attributes of final healthcare products. Some key factors that should be taken into consideration when selecting raw materials for healthcare products include sufficient

Optimal Peptides of BOC Sciences Arouse Heated Discussions at TIDES USA 2022

BOC Sciences successfully participated in TIDES USA 2022 from May 9th to 12th, at Hynes Convention Center, Boston. During the four-day exhibition, experts from BOC Sciences and global visitors are engaged in heated discussions concerning novel advances in peptide and amino acid synthesis, discovery, design, and engineering. BOC Sciences has been preparing for the world's largest gathering of pharmaceutical industry for several months. This year, it attracts a great number

A Collection of Current In-Demand COVID-19 Related Products

As the COVID-19 pandemic keeps spreading around the world with no sign of slowing down, massive research about drugs, vaccines, and other therapies is in full swing to mitigate the negative impact on human well-being. BOC Sciences offers several related products that show great benefits to the anti-epidemic activities. These include SARS-CoV-2 inhibitors and key raw materials for the production of disinfectants, test reagents, and vaccines. SARS-CoV-2 Inhibitors Vaccines are widely recognized as

BOC Sciences Provides PseudoUridines for Vaccine R&D

BOC Sciences, a vaccine raw material supplier headquartered in New York, announces providing pseudoUridine products for RNA modification to further promote the research and development of vaccines. According to BOC Sciences' latest report, its annual production of pseudoUridine (key raw material of vaccines) has ranked first in the world. Massive studies have shown that chemical modification of RNA would affect gene expression in RNA with DNA coding, assuming the actual gene

BOC Sciences Improves Its Fermentation CDMO Platform for Microbial Drug Developm …

BOC Sciences, a provider of CDMO services for the development of microbial drugs, recently announced that it has improved its fermentation CDMO platform to provide a comprehensive one-stop industrial fermentation CDMO service. In the field of biotechnology, fermentation refers to any process in which microbes multiply rapidly to produce a variety of valuable compounds. Bacteria (such as E. coli, the most commonly used microorganism in microbial fermentation), algae, fungus, and actinomycetes

BOC Sciences Diversifies Immune Checkpoint Inhibitors and Nonspecific Immune Sti …

Headquartered in Shirley, New York, the world’s reputed chemical supplier BOC Sciences announced to diversify its immune checkpoint inhibitors as well as nonspecific immune stimulation targets for scientific research targeting cancer immunotherapy (https://www.bocsci.com/tag/cancer-immunotherapy-36.html) on August 29, 2018. Traditionally, surgery, chemotherapy and radiotherapy are the most widely chosen therapies in cancer treatment. However, in recent years, immunotherapy has attracted increasing attention among the research community. Immunotherapy agents do not directly

BOC Sciences Launched Impurities for Scientific Research

BOC Sciences, headquartered in Shirley, New York, announced that a rich collection of impurities are now available for scientific research use on July 27, 2018. In the process of drug development and manufacturing, profiling and controlling impurities level is of considerable importance as their side pharmaceutical effects may affect the efficacy and safety of active pharmaceutical ingredients (APIs). In most cases, an exceeding amount of impurity level would lead

Go To Page:   1 2 3 4 5 6 7 8 9 10